Yesterday, President Trump released his budget proposal for the 2019 fiscal year. On the same day, the Proceedings of the National Academy of Sciences of the United States of America released a paper summarizing the NIH’s contribution of funding to new drugs approved from 2010 to 2016.
Yesterday, President Trump released his budget proposal for the 2019 fiscal year. Under the proposed plan, the National Institutes of Health (NIH) budget for 2019 would remain about equal to its 2017 budget: $34.8 billion. However, this figure would be roughly $2 billion less than the 2018 budget that was just approved by Congress on February 8.
Within the proposed budget, the White House calls for the creation of a National Institute for Research on Safety and Quality (replacing the Agency for Healthcare Research and Quality under HHS); the transfer of the National Institute of Disability, Independent Living, and Rehabilitation Research from HHS to the NIH; and the transfer of the National Institute of Occupational Safety from the NIH to the Centers for Disease Control. The plan would also provide the NIH with an additional $750 million for research on the opioid crisis, of which $400 million must be spent on public-private partnerships.
On the same day that Trump put forward his budget proposal, the Proceedings of the National Academy of Sciences of the United States of America (PNAS) released a paper summarizing the NIH’s contribution of funding to new drugs approved from 2010 to 2016.
The report’s authors identified NIH-funded publications and projects that were directly related to each of the 210 new molecular entities (NMEs) (or their molecular targets) approved by the FDA over the timespan of 2010 to 2016. The NIH research comprised more than 200,000 funding years and project costs that totaled more than $100 billion. The analysis suggests that as much as 20% of the NIH budget allocation from 2000 to 2016 was associated with research that directly or indirectly contributed to the NMEs approved between 2010 and 2016.
“These data demonstrate that a sizable public-sector investment occurs before the approval of first-in-class NMEs, particularly those discovered using targeted discovery methods (including recombinant biologicals),” noted the authors, who added that “This work shows that a large fraction of the NIH research budget is focused on the basic research required to bring new products to market. Any reduction in this funding that slows the pace of this research could significantly delay the emergence of new drugs in the future."
Reference:
Cleary EG, Beierlein JM, Khanuja NS, McNamee LM, Ledley FD. Contribution of NIH funding to new drug approvals 2010-2016. Proc Natl Acad Sci USA. https://doi.org/10.1073/pnas.1715368115. Published online February 12, 2018. Accessed February 13, 2018.
Julie Reed: Why 2024 Is Important for Biosimilars
April 17th 2024Julie Reed, executive director of the Biosimilars Forum, showcases how the biosimilar industry is expected to develop throughout 2024, including major policy changes and hope for continued improvement in market share for adalimumab biosimilars.
Exploring the Biosimilar Horizon: Julie Reed's Predictions for 2024
February 18th 2024On this episode of Not So Different, Julie Reed, executive director of the Biosimilars Forum, returns to discuss her predictions for the biosimilar industry for 2024 and beyond as well as the impact that the Forum's 4 new members will have on the organization's mission.
BioRationality: Removing the Misconceptions Surrounding Interchangeability
April 15th 2024Sarfaraz K. Niazi, PhD, outlines the current state of interchangeable biosimilars in the US and policy changes needed to clear up misconceptions surrounding the meaning behind interchangeability designations.
A New Chapter: How 2023 Will Shape the US Biosimilar Space for 2024 and Beyond
December 31st 2023On this episode of Not So Different, Cencora's Brian Biehn and Corey Ford take a look back at major policy and regulatory advancements in 2023 and how these changes will alter the space going forward.
Biosimilars Council: PBM Rebate Schemes Cost Americans, Payers $6 Billion
April 10th 2024A report from the Biosimilars Council evaluating IQVIA data found that rebate schemes orchestrated by pharmacy benefit managers (PBMs) are costing US patients and payers billions of dollars by suppressing biosimilar adoption.
Rising Biosimilar Adoption for an Italian Payer Will Benefit National Health Care System, Patients
April 9th 2024Data from 2021 and 2022 indicates increasing biosimilar use in an Italian health care company, with potential for full adoption in the future, benefiting both the National Health System and citizens through efficient and sustainable health care policies.